Some antiretroviral agentsinduce profound metabolic changes which may result in lipoatrophy/lipodystrophy, metabolic syndrome, type 2 diabetes and related disorders. The evidence linking antiretroviral therapy to enhanced risk of type 2 diabetes in the HIV+ patient on cART is reviewed and the potential relations with cardiovascular risk are highlighted. Current options in diabetes preventative therapy are also examined.
Keywords: Diabetes; HIV.
Articolo presente in – HAART and correlated pathologies n. 3 –